Fotil eye drops 5ml

Fotil eye drops - is a combined preparation based on pilocarpine alkaloid and timolol beta-adrenoblocker, the combined effect of which leads to a decrease in intraocular pressure in various types of glaucoma, and also after surgical interventions on the organ of vision

Fotil eye drops - combined antiglaucoma preparation.

Pilocarpine is an m-holinomimetic, with topical application it reduces the smooth muscles of the circular muscle of the iris and ciliary muscle, which leads to an increase in the angle of the anterior chamber of the eye, a change in the configuration of the trabecular zone. This helps to increase the outflow of intraocular fluid from the anterior chamber of the eye and decrease the intraocular pressure.

Timolola maleate - beta-blocker, prevents the stimulating effect of catecholamines on β-adrenergic receptors. Reduces intraocular pressure by reducing the formation of intraocular fluid.

Pilocarpine and timolol with a combination in one preparation mutually reinforce each other.

With topical application, Fotil reduces both increased and normal intraocular pressure, irrespective of the presence of glaucoma. After a single application of a single dose of Fotil, intraocular pressure begins to decrease after 30 minutes, the maximum effect is usually achieved after 2 hours, the effect of the drug is maintained for 20 hours.

Pharmacokinetics

Timolol

Rapidly penetrates through the cornea.

Reducing the formation of intraocular fluid, reduces the rate of excretion of pilocarpine from the eye.

Pilocarpine

Well penetrates through the cornea. C max in the intraocular fluid is achieved after 30 min. Pilocarpine binds in most tissues of the eye, which prolongs its half-life from the eye, which ranges from 1.5 to 2.5 hours. Pilocarpine is unchanged from the eye tissues along with the intraocular fluid.

In blood plasma and liver quickly hydrolyzed into an inactive form. T 1/2 from blood plasma - less than 0.5 h.

Indications:

• Open angle and angle-closure glaucoma.
• Glaucoma associated with aphakia.
• Secondary glaucoma.
• Increase in intraocular pressure in the postoperative period.
• Glaucoma after surgery for cataracts.
• Pronounced increase in intraocular pressure with risk of eye damage (including as part of combined antiglaucoma therapy).

Contraindications:

• anterior uveitis;
• sinus bradycardia;
• AV blockade II and III degree;
• Decompensated heart failure;
• cardiogenic shock;
• bronchial asthma;
• COPD;
• children and adolescents under 18 years (due to the lack of data on the effectiveness and safety of the drug in children and adolescents);
• the condition immediately after ophthalmic operations and other eye diseases, in which the narrowing of the pupil is undesirable;
• hypersensitivity to the components of the drug.

With caution should prescribe the drug for heart failure, cerebrovascular disorders, diabetes, hypoglycemia, retinal detachment, myopia, thyrotoxicosis, before surgery under general anesthesia.

Special instructions:

The drug is prescribed to patients who can not compensate for increased intraocular pressure with monotherapy, in almost all forms of glaucoma.

Caution should be given to the drug in the following cases:

• Patients with cerebrovascular disorders.
• With hypoglycemia.
• Before the operation under anesthesia.

Care should be taken when prescribing the drug to patients receiving beta-blockers inwards.

With prolonged use of the drug in patients with glaucoma may develop resistance to the active components of the drug. However, to the combined eye drops the degree of development of tolerance is expressed less than to monocomponent antiglaucoma drugs.

Evaluation of the effectiveness of the drug should be carried out approximately 4 weeks after the start of treatment. Measurement of intraocular pressure should be carried out at different times of the day.

Due to the fact that the preparation contains a preservative, patients wearing soft contact lenses should be removed before using drops. It is recommended that you wait 15 minutes before reinserting contact lenses.

During the period of drug use, dark adaptation may worsen. The patient should be warned about the danger of movement in the dark.

Use in Pediatrics

Clinical trials of the safety and efficacy of the use of Fotila in children have not been conducted.

Results of experimental studies

In studies carried out on laboratory animals, there was no mutagenic effect of timolol.

At present, there is no evidence that pilocarpine has a mutagenic effect in the treatment of glaucoma in humans. However, in experimental studies, signs of mutagenicity in pilocarpine have been identified.

Impact on the ability to drive vehicles and manage mechanisms

Drivers of vehicles must be careful when driving in conditions of insufficient lighting, because the drug can disrupt the dark adaptation.

Suggested Use:

Assign 1 drop of the drug Fotil to the affected eye 2 times / day.

In some patients, stable decrease in intraocular pressure is achieved only after several weeks of therapy. Therefore, when evaluating the results of treatment, it is necessary to measure the intraocular pressure approximately 4 weeks after the start of treatment. If the expected decrease in intraocular pressure does not occur, Fotil forte should be prescribed (Fotil forte drops drops of ophthalmic 5 ml capsule 1 Santen AO) or, in view of the fact that further increasing of the dose does not give effect, combined therapy with inhibitors of carbonic anhydrase for systemic use.

Before starting therapy with Fotil, treatment with other antiglaucoma eye drops should be discontinued the day before.

Packaging:

• Comes in original packaging. Item is brand new and unopened.

Storage:

• Keep away from direct sunlight.
• Keep locked and away from children.
• Store in dry place at room temperature.
• Do not exceed storage temperature higher than 25 C

Important notice- the outer box design may vary before prior notice!